The global kidney cancer drugs market size is expected to be
valued at USD 6.3 billion by 2022, as per a new report by Grand View Research,
Inc., registering a CAGR of 5.4% during the forecast period. Market growth is
largely driven by factors such as availability of novel drugs and presence of a
strong pipeline. Growth can also be attributed to rise in incidence of renal
cancer due to growing geriatric population and changes in lifestyle such as
increased smoking and intake of alcohol.
In 2012, kidney cancer was the 13th most
prevalent cancer worldwide, accounting for approximately 2.0% of all adult
malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer
cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas.
Various forms of cancer treatment methods have been implemented among the
currently approved drugs, including immune modulation therapy, cytokine
therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF)
inhibitor.
Browse full research report on Kidney
Cancer Drugs Market: https://www.grandviewresearch.com/industry-analysis/kidney-cancer-drugs-market
Further key
findings from the report suggest:
- Increasing incidence of the disease and rising
geriatric population globally are amongst major factors stimulating market
growth
- Novel agents have expanded market
opportunities through larger number of patients under treatment and better
treatment prospects compared to traditional therapies. The notable
clinical profile of immuno-oncology drugs is reflected their rapid uptake
and expansion of indications
- The current treatment landscape in metastatic
and advanced RCC will shift from TKI and mTOR inhibitors to specific
immuno-oncology agents like immune checkpoint inhibitors (ICI), which have
demonstrated positive results on PFS as monotherapy (Opdivo) or
combination therapy (Opdivo+Yervoy)
- U.S. accounted for more than 35.0% of the
market in 2016 due to increasing incidence of renal cell carcinoma and
presence of key manufacturers in the country. On the other hand, surge in
kidney cancer screening is a key driver in markets such as EU
- Emerging markets in Asia Pacific and Middle
East and Africa are fueled by increasing expenditure on healthcare, a
large untapped patient population base due to rise in elderly population,
and improvement in diagnostic technologies
- Some of the key players operating in this
market are Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, and
Exelixis. Collaborations for development, broader product portfolios, and
regional expansion in emerging markets are key strategic undertakings of
these companies to increase market share.
Browse request sample of this report by
Grand View Research: https://www.grandviewresearch.com/industry-analysis/kidney-cancer-drugs-market/request/rs1
Grand
View Research has segmented the global kidney cancer drugs market based on
therapeutic class, pharmacologic class, and country:
Kidney Cancer
Drugs Therapeutic Class Outlook (USD Million, 2016 - 2022)
- Targeted Therapy
- Immunotherapy
Kidney Cancer
Drugs Pharmacologic Class Outlook (USD Million, 2016 - 2022)
- Angiogenesis
Inhibitors
- mTOR Inhibitors
- Monoclonal
Antibodies
- Cytokine
Immunotherapy (IL-2)
Kidney Cancer
Drugs Country Outlook (USD Million, 2016 - 2022)
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment